TrialHuman vaccines & immunotherapeutics2026

Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation study.

Isabel Leroux-Roels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.